surpass trial tirzepatide SURPASS-5: lowers HbA1c in adults with type 2 diabetes on insulin glargine Tirzepatide: A Systematic Update

found no improvements in bone strength or microarchitecture with liraglutide, suggesting that the effects of GLP-1 receptor agonists on bone remodeling may be context-dependent and influenced by metabolic conditions

Efficacy is on par with injectable semaglutide with up to 1.7% reduction on the highest dose, and change in fasting glucose from -30 to -42mg/dl which is a significant improvement in glycemia

The generic version of Zoloft offered by Nurx contains the same active ingredient and works just as effectively as the brand-name version

Patients with RA with CKD have an increased risk of cardiovascular disease regardless of other classical CVD risk factor, and the decrease in kidney function limits RA treatment options (161, 162)